The case for phosphatidylserine: why your brain needs specific fats

The case for phosphatidylserine: why your brain needs fat

Phosphatidylserine is a phospholipid that makes up roughly 15% of total brain lipids and sits in the inner leaflet of every neuron's cell membrane. In a 2010 randomised controlled trial of 78 older adults, supplementation at 300mg daily for 6 months produced statistically significant improvements in memory recall compared to placebo - p<0.05, effect size moderate. That's not a headline. That's a data point worth understanding properly.

What the evidence actually shows

The most robust clinical work on phosphatidylserine comes from studies in older adults with age-associated memory impairment. Kato-Kataoka et al. (2010) ran a double-blind RCT with 78 participants aged 50-69. Those taking 300mg/day of soy-derived phosphatidylserine for 6 months showed significantly better performance on memory tests - specifically delayed verbal recall - compared to placebo. The effect was most pronounced in participants who had relatively low baseline memory scores.

Earlier work using bovine-derived phosphatidylserine was even more consistent. Crook et al. (1991) conducted a 12-week RCT in 149 patients with age-associated memory impairment. The treatment group (300mg/day) showed statistically significant improvements across multiple cognitive tests, including tasks measuring learning, recall, and concentration. The authors noted that a subset of participants - those with less severe baseline impairment - showed the most pronounced response.

A meta-analysis by Richter et al. (2013) reviewed 11 RCTs and concluded there was consistent evidence for phosphatidylserine's effect on memory and cognitive function in older adults, with a pooled effect size in the small-to-moderate range. I'd describe the evidence base as solid for this population. For younger, healthy adults, the picture is thinner - more on that shortly.

What's actually happening in the brain

Phosphatidylserine isn't a signal molecule or a neurotransmitter. It's structural. It forms part of the lipid bilayer of neuronal cell membranes - specifically concentrated on the cytoplasmic face of the membrane, where it influences membrane fluidity, receptor conformation, and ion channel function.

A few mechanisms are worth understanding:

• Acetylcholine release: Phosphatidylserine supports the activity of choline acetyltransferase and facilitates acetylcholine release at synapses. Acetylcholine is central to memory encoding and attention. This is why the research signal is strongest in conditions where cholinergic function is declining.
• Glucose metabolism: Neuronal membranes rich in phosphatidylserine appear to support more efficient glucose uptake and utilisation. Cenacchi et al. (1987) noted improved cerebral glucose metabolism in patients supplemented with phosphatidylserine - though this study was small and the methods are dated by modern standards.
• HPA axis modulation: This is the mechanism I find most interesting. Phosphatidylserine has a blunting effect on cortisol release in response to physical and psychological stress. Monteleone et al. (1992) showed that 800mg/day attenuated ACTH and cortisol responses to exercise stress in a crossover trial of 9 men. The effect was dose-dependent. Chronically elevated cortisol is genuinely damaging to hippocampal tissue, so this mechanism has real downstream relevance for cognitive health.
• Membrane repair and apoptosis signalling: In healthy cells, phosphatidylserine stays on the inner membrane leaflet. When a cell is damaged or undergoing apoptosis, it flips to the outer leaflet - a signal for immune clearance. Adequate phosphatidylserine availability supports the integrity of this signalling system.

None of this is exotic biochemistry. It's the kind of foundational membrane biology that gets overlooked because it doesn't make for exciting marketing copy. But it's exactly why the compound has a plausible mechanism - and why I take it seriously.

Dosing: what the clinical evidence supports

The dose used across the majority of positive RCTs is 300mg/day, split across meals. This appears to be the threshold at which meaningful effects on memory and cortisol regulation emerge in most studies. Some trials have used up to 800mg/day - particularly in the cortisol-blunting research - but the incremental benefit above 300mg for cognitive outcomes specifically isn't well established.

Kato-Kataoka et al. (2010) used 300mg in their soy-derived PS trial. Crook et al. (1991) also used 300mg. The consistency here is useful - it suggests 300mg is a reasonable target rather than an arbitrary number.

One practical note: phosphatidylserine is fat-soluble. Taking it with a meal that contains some fat improves absorption. This is one of those details that rarely appears on product labels but matters for how much of what you're taking actually reaches the brain.

If you're looking at a product and the phosphatidylserine dose is buried in a proprietary blend with no individual disclosure, you have no way of knowing whether you're getting 300mg or 30mg. I've written at length about this problem - it's worth reading why supplement labels lie before you buy anything in this category.

Soy-derived versus bovine-derived: does the source matter?

This is a legitimate question and the answer is nuanced. The original clinical trials - including the work that led the US FDA to grant a qualified health claim for phosphatidylserine in 2003 - largely used bovine cortex-derived PS. Bovine PS has a fatty acid profile that's particularly rich in DHA (docosahexaenoic acid), which is the dominant omega-3 in brain tissue.

Soy-derived PS, which is now the industry standard due to BSE concerns, has a different fatty acid profile - predominantly linoleic acid rather than DHA. Some researchers have questioned whether this changes the efficacy. Richter et al. (2013) found positive results with soy-derived PS in their meta-analysis, suggesting the effect isn't entirely dependent on the bovine fatty acid profile. But the honest answer is that the head-to-head comparison data is limited.

There's an argument - and I find it persuasive - that combining soy-derived PS with an algal DHA source may approximate the fatty acid environment of the original bovine formulations more closely. Algal DHA is the same molecule as fish-oil DHA but without the sustainability concerns. This is part of the reasoning behind including algal DHA in Kojo's formulation, where DHA contributes to normal brain function - an authorised claim under UK nutrition regulations.

The cortisol connection: stress, memory, and the HPA axis

Cortisol is often framed as simply "the stress hormone" - which undersells how specifically damaging chronic elevation is to memory function. The hippocampus, the brain region most directly involved in forming new memories, has a high density of glucocorticoid receptors. Sustained cortisol exposure shrinks hippocampal volume and impairs neurogenesis. This is well-established neuroscience, not speculation.

The phosphatidylserine-cortisol relationship is one of the more interesting aspects of the research. Monteleone et al. (1992) showed significant attenuation of cortisol response at 800mg/day. A follow-up study by Benton et al. (2001) in younger adults found mood and cognitive effects that the authors partly attributed to HPA modulation, though the sample was small (n=36) and results should be interpreted cautiously.

What I find compelling about this mechanism is that it's not about blocking cortisol entirely - which would be problematic, since cortisol has legitimate functions. It's about attenuating an exaggerated stress response. That's a meaningful distinction.

What the evidence doesn't support - being honest about the limits

The research on phosphatidylserine in younger, healthy adults is genuinely thin. Most of the strong RCT data is in older adults with some degree of cognitive decline or age-associated memory impairment. Extrapolating those findings to a 28-year-old looking for a focus edge is a stretch I'm not comfortable making without qualification.

There are a handful of studies in younger populations. Hirayama et al. (2014) looked at children with ADHD-like symptoms and found some benefit, but that's a specific clinical population. The data on healthy young adults doing cognitively demanding work is sparse and I'd be overstating it to claim otherwise.

Similarly, the long-term safety data beyond 6 months is limited. The existing trials don't suggest any concerning signals, but "no red flags in short-term trials" isn't the same as a clean long-term safety record.

One more thing: phosphatidylserine doesn't work in isolation. It's a membrane component. Its efficacy is likely influenced by the overall quality of your dietary fat intake, your omega-3 status, and whether you're actually sleeping enough for memory consolidation to occur. Supplements don't compensate for foundational lifestyle deficits. I know that's obvious, but it bears saying.

How phosphatidylserine fits alongside other cognitive support compounds

Phosphatidylserine is structural - it supports the membrane environment in which neurotransmission happens. It works well conceptually alongside compounds that operate through different mechanisms.

Creatine monohydrate, for instance, supports cellular energy availability through the phosphocreatine system. There's reasonable evidence that creatine supports cognitive performance under conditions of sleep deprivation and mental fatigue - a different pathway entirely from membrane phospholipid support. Creatine increases physical performance in successive bursts of short-term, high intensity exercise, and its role in brain energy metabolism is an active area of research.

Lion's mane mushroom (Hericium erinaceus) is another compound worth understanding in this context - it appears to influence nerve growth factor synthesis through a completely different mechanism. I've covered the evidence on lion's mane benefits separately, and the short version is: interesting early data, limited large-scale human trials, honest uncertainty about effect magnitude.

The point isn't to stack everything together and hope for additive effects. It's to understand what each compound does mechanistically and whether the combination makes biological sense. Phosphatidylserine's structural role is distinct enough that it doesn't obviously compete with or duplicate other common cognitive compounds.

A note on the omega-3 and DHA relationship

Phosphatidylserine doesn't exist in the brain as a standalone molecule - it exists as part of a phospholipid bilayer that's heavily influenced by the availability of long-chain polyunsaturated fatty acids, particularly DHA. The brain is roughly 60% fat by dry weight, and DHA accounts for a disproportionate share of that in neuronal membranes.

Kidd (2007) reviewed the interaction between PS and DHA and argued that the two compounds are functionally interdependent - that PS supplementation may be more effective when DHA status is adequate, because DHA is the preferred fatty acid incorporated into PS molecules in neuronal membranes. This is a plausible hypothesis. The direct evidence for the combination being superior to either alone is still preliminary, but the mechanistic rationale is sound.

Algal DHA is the same molecule as marine-derived DHA. For those who don't eat oily fish regularly - and most people in the UK don't meet recommended omega-3 intakes - algal DHA is a practical way to support the membrane environment that phosphatidylserine depends on.

Frequently asked questions

My honest take

I came to phosphatidylserine the way I come to most compounds - sceptically, through the primary literature, looking for reasons to discount it. What I found was more solid than I expected. The RCT evidence in older adults is genuinely consistent. The mechanism is real and well-characterised. The cortisol-blunting data is interesting in a way that goes beyond the typical "nootropic" framing.

What I'm less certain about is the relevance for people in their twenties and thirties without existing cognitive decline. The honest answer is that the evidence doesn't strongly support it for that group, and I won't pretend otherwise. If you're healthy, sleeping adequately, eating oily fish twice a week, and managing stress reasonably well, the marginal benefit of PS supplementation is probably small. If any of those things are consistently not true - particularly the omega-3 intake and the stress management - the case is more interesting.

What I'm confident about is this: phosphatidylserine is one of the few compounds in the cognitive health space with a plausible mechanism, replicated RCT data, and a reasonable safety profile. That puts it in a fairly small category. The supplement industry is full of compounds that have one of those three things. Having all three matters.

I also think the source and dose transparency question is underappreciated. 300mg of a well-characterised soy-derived PS is a different thing from an undisclosed amount in a proprietary blend. The compound can only do what the evidence suggests if you're actually getting the dose the evidence used. That sounds obvious. It apparently isn't, given how most products in this category are labelled.

The full picture on the case for phosphatidylserine: why your brain needs specific fats is one worth reading carefully before drawing conclusions. The evidence is interesting. It's also more limited than most marketing suggests. Both things are true.